1. Agca, R, Heslinga, SC, Rollefstad, S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76:17-28.
Google Scholar | Crossref | Medline | ISI2. Liao, KP . Cardiovascular disease in patients with rheumatoid arthritis. Trends Cardiovasc Med. 2017;27:136-140.
Google Scholar | Crossref | Medline3. Charles-Schoeman, C . Cardiovascular disease and rheumatoid arthritis: an update. Curr Rheumatol Rep. 2012;14:455-462.
Google Scholar | Crossref | Medline | ISI4. Skeoch, S, Bruce, IN. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol. 2015;11:390-400.
Google Scholar | Crossref | Medline | ISI5. Babaeva, A, Kalinina, EV, Zvonorenko, MS, Solodenkova, KS, Osadchuk, MA. Cardiovascular risk evaluation in long standing rheumatoid arthritis: real clinical data. Paper presented at: Annual European Congress of Rheumatology, EULAR; June 13-16, 2018; Netherlands.
Google Scholar6. Giollo, A, Bissell, LA, Buch, MH. Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review. Expert Opin Drug Saf. 2018;17:697-708.
Google Scholar | Crossref | Medline7. Kang, EH, Liao, KP, Kim, SC. Cardiovascular safety of biologics and JAK inhibitors in patients with rheumatoid arthritis. Curr Rheumatol Rep. 2018;20:42.
Google Scholar | Crossref | Medline8. Kraakman, MJ, Dragoljevic, D, Kammoun, HL, Murphy, AJ. Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis. Clin Transl Immunol. 2016;5:e84.
Google Scholar | Crossref | Medline9. Sattin, M, Towheed, T. The effect of TNFα-inhibitors on cardiovascular events in patients with rheumatoid arthritis: an updated systematic review of the literature. Curr Rheumatol Rev. 2016;12:208-222.
Google Scholar | Crossref | Medline10. England, BR, Thiele, GM, Anderson, DR, Mikuls, TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ. 2018;361:k1036.
Google Scholar | Medline11. Soulaidopoulos, S, Nikiphorou, E, Dimitroulas, T, Kitas, GD. The role of statins in disease modification and cardiovascular risk in rheumatoid arthritis. Front Med (Lausanne). 2018;5:24.
Google Scholar | Crossref | Medline12. Nossent, J, Raymond, W, Divitini, M, Knuiman, M. Rheumatoid factors do not predict cardiovascular disease and mortality in the general population in the Busselton Health Survey. BMC Musculoskelet Disord. 2017;18:221.
Google Scholar | Crossref | Medline13. Tomasson, G, Aspelund, T, Jonsson, T, Valdimarsson, H, Felson, DT, Gudnason, V. Effect of rheumatoid factor on mortality and coronary heart disease. Ann Rheum Dis. 2010;69:1649-1654.
Google Scholar | Crossref | Medline14. Okano, T, Inui, K, Sugioka, Y, et al. High titer of anti-citrullinated peptide antibody is a risk factor for severe carotid atherosclerotic plaque in patients with rheumatoid arthritis: the TOMORROW study. Int J Rheum Dis. 2017;20:949-959.
Google Scholar | Crossref | Medline15. Geraldino-Pardilla, L, Giles, JT, Sokolove, J, et al. Association of anti-citrullinated peptide antibodies with coronary artery calcification in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2017;69:1276-1281.
Google Scholar | Crossref | Medline16. Higgins, J, Green, S. Handbook for Systematic Reviews of Interventions 2011. Version 5.1.0. Accessed October 18, 2018. http://handbook.cochrane.org
Google Scholar17. Higgins, JP, Altman, DG, Gøtzsche, PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
Google Scholar | Crossref18. Wells, G, Shea, B, O’Connell, D, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. 2000. Accessed October 18, 2018. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
Google Scholar19. Davies, R, Thompson, CR, Jin, HS, et al. Patients with early rheumatoid arthritis have increased cardiovascular risk at the time of diagnosis [abstract]. Paper presented at: Annual European Congress of Rheumatology, EULAR; June 14-17, 2017; Spain.
Google Scholar20. Kerola, AM, Kauppi, MJ, Kerola, T, Nieminen, TV. How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear? Ann Rheum Dis. 2012;71:1606-1615.
Google Scholar | Crossref | Medline | ISI21. Kokkonen, H, Arlestig, L, Rantapaa-Dahlqvist, S. Risk factors for cardiovascular disease predate the onset of symptoms of rheumatoid arthritis [abstract]. Paper presented at: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP; November 11-16, 2016; United States.
Google Scholar22. Van Boheemen, L, Van Beers-Tas, M, Van Schaardenburg, D, Nurmohamed, MT. Lipid profile and cardiovascular risk in subjects at risk for developing rheumatoid arthritis [abstract]. Paper presented at: Annual European Congress of Rheumatology, EULAR; June 13-16, 2018; Netherlands.
Google Scholar23. Im, CH, Kim, NR, Kang, JW, et al. Inflammatory burden interacts with conventional cardiovascular risk factors for carotid plaque formation in rheumatoid arthritis. Rheumatology (Oxford). 2015;54:808-815.
Google Scholar | Crossref | Medline24. Khimion, LV, Klymas, IV, Naishtetik, IM. Comorbidities and risk factors of cardiovascular diseases in rheumatoid arthritis patients [abstract]. Paper presented at: Annual European Congress of Rheumatology, EULAR; June 14-17, 2017; Spain.
Google Scholar25. Primdahl, J, Clausen, J, Hørslev-Petersen, K. Results from systematic screening for cardiovascular risk in outpatients with rheumatoid arthritis in accordance with the EULAR recommendations. Ann Rheum Dis. 2013;72:1771-1776.
Google Scholar | Crossref | Medline26. Barbhaiya, M, Solomon, DH. Rheumatoid arthritis and cardiovascular disease: an update on treatment issues. Curr Opin Rheumatol. 2013;25:317-324.
Google Scholar | Crossref | Medline27. Baghdadi, LR, Woodman, RJ, Shanahan, EM, Mangoni, AA. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One. 2015;10:e0117952.
Google Scholar | Crossref | Medline28. Crowson, CS, Rollefstad, S, Ikdahl, E, et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77:48-54.
Google Scholar | Crossref | Medline29. Lauper, K, Gabay, C. Cardiovascular risk in patients with rheumatoid arthritis. Semin Immunopathol. 2017;39:447-459.
Google Scholar | Crossref | Medline30. Myasoedova, E, Crowson, CS, Kremers, HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70:482-487.
Google Scholar | Crossref | Medline | ISI31. Venetsanopoulou, AI, Pelechas, E, Voulgari, PV, Drosos, AA. The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk. Rheumatol Int. 2020;40:1181-1191.
Google Scholar | Crossref | Medline32. Zanatta, E, Colombo, C, D’Amico, G, d’Humieres, T, Dal Lin, C, Tona, F. Inflammation and coronary microvascular dysfunction in autoimmune rheumatic diseases. Int J Mol Sci. 2019;20:5563.
Google Scholar | Crossref33. Aletaha, D, Blüml, S. Therapeutic implications of autoantibodies in rheumatoid arthritis. RMD Open. 2016;2:e000009.
Google Scholar | Crossref34. Song, Y, Kang, E. Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. QJM. 2009;103:139-146.
Google Scholar | Crossref | Medline35. Geraldino-Pardilla, L, Russo, C, Sokolove, J, et al. Association of anti-citrullinated protein or peptide antibodies with left ventricular structure and function in rheumatoid arthritis. Rheumatology (Oxford). 2017;56:534-540.
Google Scholar | Medline36. Sokolove, J, Brennan, MJ, Sharpe, O, et al. Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. Arthritis Rheum. 2013;65:1719-1724.
Google Scholar | Crossref | Medline37. Giles, JT, Fert-Bober, J, Park, JK, et al. Myocardial citrullination in rheumatoid arthritis: a correlative histopathologic study. Arthritis Res Ther. 2012;14:R39.
Google Scholar | Crossref38. Sokolove, J, Johnson, DS, Lahey, LJ, et al. Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol. 2014;66:813-821.
Google Scholar | Crossref | Medline39. Verbrugge, FH, Tang, WH, Hazen, SL. Protein carbamylation and cardiovascular disease. Kidney Int. 2015;88:474-478.
Google Scholar | Crossref | Medline40. Wu, CY, Yang, HY, Luo, SF, Lai, JH. From rheumatoid factor to anti-citrullinated protein antibodies and anti-carbamylated protein antibodies for diagnosis and prognosis prediction in patients with rheumatoid arthritis. Int J Mol Sci. 2021;22:686.
Google Scholar | Crossref41. Treharne, GJ, Hale, ED, Lyons, AC, et al. Cardiovascular disease and psychological morbidity among rheumatoid arthritis patients. Rheumatology (Oxford). 2005;44:241-246.
Google Scholar | Crossref | Medline42. Scherrer, JF, Virgo, KS, Zeringue, A, et al. Depression increases risk of incident myocardial infarction among Veterans Administration patients with rheumatoid arthritis. Gen Hosp Psychiatry. 2009;31:353-359.
Google Scholar | Crossref | Medline43. Kurko, J, Besenyei, T, Laki, J, Glant, TT, Mikecz, K, Szekanecz, Z. Genetics of rheumatoid arthritis – a comprehensive review. Clin Rev Allergy Immunol. 2013;45:170-179.
Google Scholar | Crossref | Medline | ISI44. Karami, J, Aslani, S, Jamshidi, A, Garshasbi, M, Mahmoudi, M. Genetic implications in the pathogenesis of rheumatoid arthritis; an updated review. Gene. 2019;702:8-16.
Google Scholar | Crossref | Medline45. Snir, O, Montes, A, Perez-Pampin, E, et al. Non-HLA genes PTPN22, CDK6 and PADI4 are associated with specific autoantibodies in HLA-defined subgroups of rheumatoid arthritis. Arthritis Res Ther. 2014;16:414.
Google Scholar | Crossref | Medline46. Danninger, K, Hoppe, UC, Pieringer, H. Do statins reduce the cardiovascular risk in patients with rheumatoid arthritis? Int J Rheum Dis. 2014;17:606-611.
Google Scholar | Crossref | Medline | ISI47. Solomon, DH, Reed, GW, Kremer, JM, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 2015;67:1449-1455.
Google Scholar | Crossref | Medline48. Ruyssen-Witrand, A, Fautrel, B, Saraux, A, Le Loët, X, Pham, T. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine. 2011;78:23-30.
Google Scholar | Crossref | Medline | ISI49. Popkova, TV, Novikova, DS, Gasparyan, AY, Nasonov, EL. Cardiovascular effects of methotrexate in rheumatoid arthritis revisited. Curr Med Chem. 2015;22:1903-1910.
Google Scholar | Crossref | Medline50. Toussirot, É . Effects of TNFα inhibitors on adiposity and other cardiovascular risk factors: implications for the cardiovascular prognosis in patients with rheumatoid arthritis. Expert Opin Drug Saf. 2015;14:525-532.
Google Scholar | Crossref | Medline51. Kim, SC, Solomon, DH, Rogers, JR, et al. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: a multi-database cohort study. Semin Arthritis Rheum. 2018;48:399-405.
Google Scholar | Crossref | Medline